Mixed Lymphocyte Tumor Reactivity Assay Service

The Mixed Lymphocyte Tumor Reactivity (MLTR) assay is a sophisticated in vitro co-culture system designed to model and quantify tumor antigen-specific T cell immune responses. Leveraging our robust, high-throughput screening platform, Creative Biolabs' Mixed Lymphocyte Tumor Reactivity Assay Service provides a standardized and reproducible solution for evaluating cell-based immunotherapies. Our optimized platform ensures the generation of highly reliable, multiparameter data on T cell activation, proliferation, and cytotoxic function with minimal variability. We thereby empower you with critical preclinical insights to de-risk decision-making, optimize candidate selection, and significantly accelerate immuno-oncology drug development pipeline.

Introduction

Mixed Lymphocyte Reactivity (MLR) is the classic in vitro paradigm in which immune-competent cells from two allogeneic donors are co-cultured, triggering proliferation and cytokine release through reciprocal recognition of foreign MHC molecules. MLTR extends this platform by incorporating autologous or allogeneic tumor cells, generating a tripartite "immune-tumor" co-culture that faithfully recapitulates tumor-antigen–specific T cell priming and effector phases. The model offers an early, integrated read-out of therapy-induced expansion, phenotypic polarization, and cytotoxic capacity of tumor-reactive T cells, supplying both mechanistic insight and dose-ranging data for subsequent in vivo studies. Consequently, implementing a standardized, high-sensitivity MLTR assay is an indispensable checkpoint in the cancer immunotherapy drug-discovery pipeline.

Fig.1 Sulfavant A induces a tolerogenic shift in mixed lymphocyte reactivity.¹

Mixed Lymphocyte Tumor Reactivity Service at Creative Biolabs

Creative Biolabs' Mixed Lymphocyte Tumor Reactivity Service is designed to provide clear and actionable insights into the immune interactions between lymphocytes and tumor cells. Utilizing a robust experimental platform, our service systematically evaluates T cell activation, proliferation, and cytotoxic responses upon exposure to tumor antigens, key aspects in the development of novel cancer immunotherapies. Through precise and reliable detection methods, the assay effectively assesses the potential of your therapeutic candidates to induce anti-tumor immune responses.

What we can offer

Our service leverages state-of-the-art techniques to provide an in-depth assessment of T-cell cytotoxic efficacy, delivering actionable insights for your research.

Our Service Process

Required Starting Materials:

• A lymphocyte population (e.g., from Peripheral Blood Mononuclear Cells).
• A target tumor cell line or primary tumor cells.
• The therapeutic agent(s) to be tested.

Key Steps Involved:

Final Deliverables: Upon completion, you will receive a detailed report including raw data, analyzed graphs (e.g., dose-response curves), and a professional interpretation of the results.

Key Advantages

• Advanced multiparameter profiling: We deliver a correlated view of immune reactivity, quantifying T-cell proliferation, activation markers, and cytokine/chemokine secretion in a single assay.
• A stringent quality management system: Our system supported by robust and standardized protocols ensures exceptional data stability and inter-assay reproducibility.
• High-throughput screening compatibility: We provide efficient evaluation of numerous compounds and concentration gradients to significantly accelerate lead candidate identification.

FAQ

Why Choose Us?

Our MLTR assay delivers validated, high-quality data to advance your immuno-oncology research. Our robust and high-throughput platform accelerates the screening of therapeutic candidates by providing reliable and reproducible results with significant gains in efficiency and cost-effectiveness.

Customer Reviews

"Integrating Creative Biolabs' MLTR Assay Service into our research workflow greatly enhanced the characterization of our lead candidate's mechanism of action. The multi-parametric output, including proliferation and cytokine release metrics from a single assay plate, provided critical insights that supported deeper mechanistic understanding." Dr. B***n, R&D Director.

"Creative Biolabs' MLTR assay delivered highly specific and reproducible data, which played a key role in verifying the anti-tumor efficacy of our engineered T cell therapy. The assay's robustness made it an essential component of our validation pipeline." A. J***s, Senior Scientist.

"In a comparative assessment with in-house methods, Creative Biolabs' high-throughput MLTR platform demonstrated superior efficiency. The capability to screen numerous compounds and concentrations concurrently resulted in significant savings in time and resources." Dr. S***t, Project Lead.

How to contact us?

Unlock key insights into your immuno-oncology candidates with our Mixed Lymphocyte Tumor Reactivity Assay Service. Contact our experts to discuss how our customized solutions can advance your project.

Unlock Tailored Solutions with Our Expertise – Request Your Quote Now.

Reference

1. Barra, Giusi et al. "The immunoregulatory effect of the TREM2-agonist Sulfavant A in human allogeneic mixed lymphocyte reaction." Frontiers in immunology vol. 14 1050113. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2023.1050113.